Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
1.810
-0.020 (-1.09%)
Sep 9, 2024, 4:00 PM EDT - Market closed
Aadi Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 23.82 | 24.35 | 15.22 | 1.12 | 14.58 | 0.75 |
| Revenue Growth (YoY) | 10.57% | 60.06% | 1258.57% | -92.32% | 1846.60% | - |
| Cost of Revenue | 54.4 | 51.74 | 34 | 19.67 | 15.01 | 11.06 |
| Gross Profit | -30.58 | -27.38 | -18.78 | -18.55 | -0.43 | -10.32 |
| Selling, General & Admin | 40.08 | 44.55 | 40.18 | 18.51 | 2.12 | 1.85 |
| Operating Expenses | 40.08 | 44.55 | 40.18 | 18.51 | 2.12 | 1.85 |
| Operating Income | -70.66 | -71.93 | -58.96 | -37.06 | -2.55 | -12.17 |
| Interest Expense | -0.23 | -0.23 | -0.23 | -0.67 | -0.82 | -0.09 |
| Interest & Investment Income | 5.45 | 6.4 | 2.4 | 0.01 | 0.04 | 0.01 |
| Currency Exchange Gain (Loss) | -0 | -0 | - | - | - | - |
| EBT Excluding Unusual Items | -65.44 | -65.77 | -56.79 | -37.71 | -3.32 | -12.25 |
| Asset Writedown | - | - | -3.72 | -74.16 | - | - |
| Other Unusual Items | - | - | - | 1.78 | -0.15 | - |
| Pretax Income | -65.44 | -65.77 | -60.51 | -110.09 | -3.48 | -12.25 |
| Income Tax Expense | - | - | - | 0 | 0 | 0 |
| Net Income | -65.44 | -65.77 | -60.51 | -110.09 | -3.48 | -12.26 |
| Preferred Dividends & Other Adjustments | - | - | - | 0.65 | 0.99 | 0.99 |
| Net Income to Common | -65.44 | -65.77 | -60.51 | -110.74 | -4.47 | -13.24 |
| Shares Outstanding (Basic) | 27 | 27 | 23 | 9 | 3 | 8 |
| Shares Outstanding (Diluted) | 27 | 27 | 23 | 9 | 3 | 8 |
| Shares Change (YoY) | 5.88% | 19.58% | 152.27% | 250.99% | -68.28% | - |
| EPS (Basic) | -2.43 | -2.44 | -2.69 | -12.41 | -1.76 | -1.65 |
| EPS (Diluted) | -2.43 | -2.44 | -2.69 | -12.41 | -1.76 | -1.65 |
| Free Cash Flow | -53.6 | -63.64 | -50.08 | -22.47 | -12.7 | -7.62 |
| Free Cash Flow Per Share | -1.99 | -2.36 | -2.22 | -2.52 | -5.00 | -0.95 |
| Gross Margin | -128.40% | -112.44% | -123.43% | - | -2.94% | - |
| Operating Margin | -296.67% | -295.36% | -387.47% | -3309.02% | -17.48% | -1624.81% |
| Profit Margin | -274.77% | -270.04% | -397.69% | -9887.23% | -30.62% | -1767.91% |
| Free Cash Flow Margin | -225.05% | -261.29% | -329.15% | -2006.16% | -87.11% | -1017.33% |
| EBITDA | -70.47 | -71.76 | -58.8 | -36.96 | -2.54 | -12.16 |
| EBITDA Margin | -295.89% | -294.67% | - | - | -17.42% | - |
| D&A For EBITDA | 0.19 | 0.17 | 0.16 | 0.11 | 0.01 | 0.01 |
| EBIT | -70.66 | -71.93 | -58.96 | -37.06 | -2.55 | -12.17 |
| EBIT Margin | -296.67% | -295.36% | - | - | -17.48% | - |
| Revenue as Reported | 23.82 | 24.35 | 15.22 | 1.12 | 14.58 | 0.75 |
Source: S&P Capital IQ. Standard template. Financial Sources.